Renowned autoimmune researcher Georg Schett co-founds biotech to develop antibody therapies

Georg Schett, a German scientist noted for pioneering CAR‑T approaches in autoimmune disease, is now launching a new biotech venture.

The startup, which has not yet been named in the report, will concentrate on antibody‑based therapies rather than CAR‑T, marking a shift in focus for Schett’s entrepreneurial efforts.

Schett has built a reputation as a sought‑after scientific adviser, serving on several emerging‑company boards. His new company aims to apply his deep immunology expertise to create novel treatments for autoimmune conditions.